Non-alcoholic steatohepatitis (NASH) is a common pre-neoplastic condition of hepatocellular carcinoma (HCC). Mice with hepatocytic deletion of Pten develop NASH and HCC later in life. This model is highly valuable for studies aimed at identifying the molecular mechanism by which metabolic disorders contribute to tumor development. We applied proteomic and lipidomic profiling approaches to Pten null NASH liver and tumors. Circulating fatty acid composition was also characterized in these mice. The relevance to human NASH and HCC was further validated. This integrative proteomic and lipidomic study from mouse to human and from liver to blood, identified the following disease signatures: 1-an HCC signature: upregulated hepatic scd1/scd2, fads2 and acsl5:acsl1 ratio, elevated vaccenic and erucic acids and reduced margaric and linoleic acids in both liver and plasma; 2-a NASH signature that correlates with tumor burden: upregulated hepatic elovl6, elevated oleic, adrenic and osbond acids and reduced cervonic acid in liver and plasma; and 3-a NASH signature: reduced hepatic and circulating lignoceric and eicosapentaenoic acids. Altogether, these results demonstrate the role of lipid-modifying enzymes converting SFAs to MUFAs in HCC and the importance of an increased ratio of long chain n6-PUFAs over n3-PUFAs in NASH and HCC risk. They also highlight the relevance of the Pten null model for studies related to NASH and HCC and demonstrate that circulating lipid metabolome provides a direct read of lipid changes in the liver.
Introduction
Non-alcoholic steatohepatitis (NASH) is recognized as a common preneoplastic condition associated with hepatocellular carcinoma (HCC) (1) . Fatty acids, lipogenic proteins and fattyacid modifying enzymes may therefore play an important role in the early steps of hepatocarcinogenesis. Mice with liver specific deletion of the phosphoinositide 3-kinase (PI3K)/phosphatase and tensin homolog (Pten) represent a valuable model for such study as PTEN loss of function in hepatocytes leads to NASH and HCC later in life (2, 3) .
Through mass-spectrometry-based profiling of the liver tissues collected at different disease stages in this mouse model, we have characterized changes in the liver proteome occurring in NASH as well as in HCC. We previously reported changes for proteins of the extracellular matrix and their receptors (4). Here we are reporting changes in proteins associated with lipid metabolism. This information is further integrated with fatty acid profiles performed in both liver tissue and plasma. Relevance to human disease was also evaluated. Delineating the fatty acid and associated proteome changes in NASH and HCC represents a unique and important contribution to our understanding of the molecular mechanisms of early hepatocarcinogenesis, and to ongoing efforts to identify novel diagnostic and therapeutic targets. 
Materials and Methods

Mouse samples
Mice carrying Pten conditional knockout alleles were crossed with an Albumin (Alb)-Cre-transgenic mouse. The Alb-Cre-transgenic mice were genotyped using Cre specific primers. Protein extraction, separation and mass spectrometry analysis were performed as previously described (4) . Acquired data were processed using the X!Tandem search algorithm and PeptideProphet and ProteinProphet statistical tools. Proteins identified with a ProteinProphet score ≥ 0.9 and with at least 2 peptides were selected. In our data sets, a 0.9 ProteinProphet score corresponds to a rate of misclassification of 1%. Relative abundance scores were calculated for individual proteins based on total peptide counts normalized to account for the total amount of protein in the mixture.
Human samples
Plasma samples were collected following informed consent from patients enrolled at (5) . The presence of cirrhosis and/or NASH was defined by histology. All NASH patients followed these criteria: absence of HCV RNA and hepatitis B virus surface antigen, self-reported alcohol consumption in the preceding six months, or histological features suggestive of primary biliary cirrhosis, autoimmune hepatitis, or iron overload. For hepatic histology assessment, steatosis, ballooning degeneration, inflammation, and fibrosis were scored according to the currently accepted scoring system. In this scoring system, the scores for steatosis grade (0-3), lobular inflammation (0-3), and ballooning (0-2) can be summed to yield a NAFLD Activity Score (NAS) with scores ≥ 5 being considered diagnostic for histological steatohepatitis. A total of 30 patients, including 15 patients with HCC and 15 patients with cirrhosis, were selected for this study. The characteristics of these patients are shown in Table S1 .
Quantitative PCR and western-blot
Total RNA was extracted from individual mouse liver tissue and purified using the miRNeasy extraction kit (Qiagen). RNA samples were then submitted to reverse transcription and real-time PCR using specific primers listed in Table S2 . cDNA equivalent was amplified with the iCycler MyiQ using SYBR green supermix and analyzed by MyiQ software (Bio-Rad Laboratories) and relative quantification of RNA expression was calculated with the 2 -ΔΔCt method. 18S quantification was used for normalization.
Mouse liver proteins (20µg) were separated on a 10% SDS-PAGE gel and transferred to nitrocellulose membranes (Trans-blot, Biorad, USA ). The membranes were incubated with primary antibodies against Fads1(ab126706, Abcam) and Scd1 (ab19862, Abcam) at the dilution 
Fatty acids profiling
Liver tissue samples (20 mg) were homogenized in a 2:1 chloroform:methanol solution using 1.4mm stainless steel beads and bullet blender. Total lipids were extracted from the homogenized liver samples or from 140 ul of plasma as previously described (6) . Different lipids (phospholipids, free cholesterol, free fatty acids, triglycerides and cholesteryl esters) were separated by one dimensional thin layer chromatography (7) . Fatty acid methyl ester (FAME) samples were prepared by direct transesterification (8) and separated using gas chromatography Extensive mass spectrometry analysis following a multi-dimensional protein separation strategy composed of two-dimensional HPLC followed by SDS-PAGE was applied as described (4) to livers collected from the Pten null model at the steatosis stage as well as on small HCCs.
For each sample group, livers from 3-4 mice were pooled. A total of 10,707 protein isoforms, products of 8,278 individual genes were identified with a FDR of 1%. For each identified protein, protein abundance was calculated using the frequency of tandem mass spectra assigned to that protein. We previously reported that this label-free approach provides a good estimate of protein abundance in liver (9, 4).
The key enzymes of de novo fatty-acid synthesis, fatty-acid synthase (Fasn), ATP-citrate lyase (Acly) and acetyl-CoA carboxylases 1 and 2 (Acc1 and Acc2), were identified at high abundance in the Pten null livers. Significant increases in abundance were observed for all 4 proteins in Pten null NASH livers compared to control livers and their expression increased further in tumors (Fig. 1A) .
Four of the 5 acyl-CoA synthetases (ACSL), enzymes that act downstream of Fasn and convert long-chain fatty acids to acyl-CoA, were identified in the Pten null livers. Acsl1 was identified as the most abundant member of the ACSL family, in the liver of Pten null and control mice. Acsl1 expression decreased in Pten null NASH livers and further decreased in tumors. In contrast, Acls5, the second most abundant ACSL enzyme, was upregulated in the NASH livers and further increased in tumors (Fig. 1B, left (Fig. 1B, right panel) . Acsl1 mRNA was slightly down-regulated in NASH Pten null livers compared to controls but strongly down-regulated in Pten null tumors (-10.7-fold; p=0.006). The expression of Acsl1 was also highly significantly decreased in tumors compared to adjacent NASH tissues (p=0.0002). In contrast, Acsl5 mRNA expression was significantly increased in NASH Pten null livers (1.9-fold; p=0.01) and further increased although not significantly in tumors (2.4-fold; p=0.01) compared to controls.
A number of desaturases were also detected in the Pten null liver proteome ( Fatty acid elongases function with fatty acid desaturases to generate many of the long chain mono and polyunsaturated fatty acids. Elongases were not detected in the liver proteome.
We therefore measured the elongases known to be expressed in liver: Elovl1,2,5,6. While elovl2 and elovl5 expression didn't change in Pten null liver (data not shown), both elovl1 and elovl6 increased in NASH Pten null livers (2.3-fold; p=0.002 and 3.2-fold; p=0.005, respectively) and further increased in tumors (3.0-fold; p=0.0003 and 9.1-fold; p=0.02). The expression of elovl6 was also significantly higher in tumors compared to adjacent NASH tissue (p=0.05) (Fig. 1D ).
Together, these results are in agreement with an overall increase in lipid synthesis in the liver of Pten null mice and identified tumor-specific changes in lipogenic proteins. In addition, changes in fatty acid desaturases and elongases indicate potential changes in fatty acids profiles in Pten null NASH liver and tumors. Information on protein annotation, peptide numbers and sequences, is summarized in Table S3 , for all proteins identified in Pten null liver proteome and described above.
Fatty Acids Profiling in Pten null Tumors and NASH Liver
The same 18 mice (9 Pten null mice that developed tumors and 9 littermate control mice) used for the lipogenic gene expression validation described above, were selected for fatty acid profiling study. Fatty acids were extracted from the liver of the control mice as well as from tumors and adjacent NASH liver tissue from the Pten null mice. Phospholipids, cholesterol esters and free fatty acids were separated by one-dimensional thin-layer chromatography and 46 individual fatty acids in each fraction were separated by gas chromatography. Fatty acid composition in control liver, Pten null tumors and adjacent NASH liver is shown as relative weight percentages of the 46 fatty acids identified in phospholipids (Fig. 2) , free fatty acids ( Supplementary Fig. S1 ) and cholesterol esters ( Supplementary Fig. S2 ). A total of nineteen fatty acids significantly changed in abundance in Pten NASH liver compared to control liver and few among them further changed in tumors. For most fatty acids, the direction of change was consistent among the 3 types of lipids.
Saturated fatty acids (SFAs)
The overall trend among the SFAs was a decrease in NASH Pten null liver compared to controls 
Circulating Fatty Acids in Pten null Mice
We then investigated whether the same fatty acid changes could be detected in plasma. Fatty acids were extracted from the plasma of the same 18 mice (9 Pten null mice that developed tumors and 9 littermate control mice). Phospholipids, cholesterol esters and free fatty acids were processed as for the liver tissue. Fatty acid composition in these plasma samples is shown as relative weight percentages of the 46 fatty acids identified in phospholipids (Fig. 3) , free fatty acids ( Supplementary Fig. S3 ) and cholesterol esters (Supplementary Fig. S4 ). Remarkably, eighteen out of the nineteen fatty acids that showed changes in Pten null liver, presented with
Research. identical changes in the plasma of these mice. For most fatty acids, the direction of change was consistent among the three types of lipid fractions. Pten null compared to control plasma, in all three fractions. Gondoic (20:1n9) and erucic (22:1n9) acids also increased in Pten null plasma in both phospholipids and free fatty acids, while below detection limit in cholesterol esters. Finally, nervonic acid (24:1n9) significantly increased in Pten null plasma in free fatty acids. As observed in liver tissue, the greatest difference was observed in the 18:1 MUFAs with both the n7 and n9 fatty acids dramatically increased.
Saturated fatty acids (SFAs)
A
n6-Polyunsaturated fatty acids (n6-PUFAs)
While linoleic (18:2n6) and γ-linolenic (18:3n6) acids significantly decreased in all three fractions in Pten null plasma, long-chain n6 fatty acids, dihomo-γ-linolenic (20:3n6) and osbond (22:5n6) acids significantly increased in all three fractions and adrenic acid (22:4n6) increased in free fatty acids.
n3-Polyunsaturated fatty acids (n3-PUFAs)
Research. Plasma levels of α-linolenic acid (18:3n3, ALA) and eicosapentaenoic (20:5n3, EPA) acids significantly decreased in all three fractions in Pten null mice.
Correlation of Fatty Acid Changes with Tumor Size and Tumor Burden
All 9 Pten null mice selected in this study had developed tumors. The size of these tumors ranged from 0.1cm to 2.2cm (mean=0.84cm) and the number of nodules per mouse ranged from 1 to 3 (mean=2.3). To evaluate a potential role of the fatty acid changes we identified in liver tumor development and growth, we calculated for each of the 19 fatty acids described above, the correlation between their level in tumor and tumor size. We also calculated the correlation between their level in adjacent tissue and tumor burden estimated as the additive size of all tumors detected in the mouse. We finally calculated the correlation between their level in plasma and tumor burden. We selected the phospholipid fraction for this analysis as all 19 fatty acids in that fraction, were within the detection limit in both liver and plasma. The results are summarized in Table 1 . 
Circulating Fatty Acids in HCC Patients
To evaluate the relevance of these results to the human disease and to distinguish changes in circulating fatty acids that are associated with HCC or with NASH, fatty acid profiling analysis was performed blinded to clinical data, on plasma collected from 30 patients including patients with NASH-associated cirrhosis (n=7), NASH-associated HCC (n=7), HBV-associated cirrhosis (n=8) or HBV-associated HCC (n=8).
We first focused on these four fatty acids that showed correlation between tumor levels and tumor size. Plasma levels of vaccenic (18:1n7) and erucic (22:1n9) acids were significantly higher in HCC patients than in cirrhosis patients, independently of the etiology NASH or HBV (1.48-fold; p=0.0003 and 2.04-fold; p=0.0003, respectively) and plasma levels of margaric (17:0) and linoleic (18:2n6, LA) acids were significantly lower in HCC patients than in cirrhosis patients, independently of the etiology NASH or HBV (-1.12-fold; p=0.03 and -1.2-fold; p=0.0003, respectively) (Fig. 4) .
We then analyzed those four fatty acids that showed correlation between levels in adjacent tissue and tumor burden. Plasma levels of oleic (18:1n9), adrenic (22:4n6) and osbond (22:5n6) acids were significantly higher in NASH patients than in HBV patients, independently of the diagnosis of HCC or cirrhosis (1.36-fold; p<0.0001, 2.34-fold; p<0.0001 and 2.21-fold; p<0.0001, respectively) and plasma levels of cervonic acid (22:6n3) were significantly lower in NASH patients than in HBV patients, independently of the diagnosis of HCC or cirrhosis (-3.45-fold; p<0.0001) (Fig. 5) .
We finally analyzed the remaining 11 fatty acids that showed changes in Pten null liver and plasma but without any correlation with tumor size or tumor burden. Among them, circulating lignoceric (24:00) and eicosapentaenoic (20:5n3, EPA) acids were strongly decreased in NASH patients compared to HBV patients, independently of the diagnosis of HCC or cirrhosis (-1.61-fold; p=0.0002 and -3.45-fold; p<0.0001, respectively) (Fig. 6) .
Altogether, these results demonstrate a strong agreement between changes observed in the Pten null model and changes observed in human plasma.
In summary (Fig. 7) , this integrated proteomic and lipidomic study applied to a mouse to human pipeline identified lipid metabolism signatures specific to the stages in the disease progression from NASH to HCC. NASH was associated with reduced hepatic and circulating lignoceric 
DISCUSSION
Re-programming of lipogenic pathways is one of the most significant physiological alterations in tumor cells (10) . Lipogenic enzymes and fatty acids have been recently recognized as promising cancer therapeutic targets (11) . Because metabolic genes are up-regulated at an early stage of cancer, they are also considered to be candidate targets for chemo-prevention. Some of the metabolic genes and their products are also likely to serve as diagnostic tools. In HCC, a recent study has linked increased lipogenesis induced by AKT-mTORC1 to HCC development in human (12) . PTEN has also been proposed to be at the crossroad of metabolism and HCC. PTEN levels are decreased in human and rat livers with steatosis and the expression of PTEN is decreased or absent in over 50% of human HCC. In mice, Pten deletion or down-regulation by unsaturated fatty-acids induce hepatic steatosis (13, 14) . In addition, Pten null mice develop HCC later in life. Therefore, Pten null mice represent a unique model to identify the mechanisms by which metabolic deregulation is linked to HCC initiation and progression.
We previously reported extracellular matrix proteome changes in NASH liver and in tumors in this model (4) . Here, we are reporting NASH-and tumor-associated modulations of lipogenic proteins and fatty-acid modifying enzymes in this same model. Four genes in the lipogenic pathway are considered to play key roles in tumorigenesis and cancer progression, namely FASN, ACLY, ACC1 and ACC2 (10) . FASN is significantly up-regulated in a variety of cancers at an early stage and its expression is positively correlated with poor survival of patients.
In our proteome profiles, we observed an upregulation of Fasn, Acly and of the two isozymes of Acc in the Pten null NASH liver. In addition, we observed a higher increase in the expression of these enzymes in Pten null tumors. It was previously reported that eicosapentaenoic (EPA) ameliorates steatohepatitis and inhibits the development of liver adenoma and HCC in hepatocyte-specific Pten-deficient mice (16) . It was suggested that dietary EPA inhibits inflammation by decreasing the n-6/n-3 polyunsaturated fatty acids ratio. Similarly, consumption of cervonic acid (DHA) appears to protect against the development of HCC, even among subjects with HBV or HCV infection (17) .
These results are in good agreement with the observed decreased of EPA and DHA in NASH and the negative correlation of DHA with tumor burden in our model. Furthermore, n6-C22 over n3-C22 ratio positively correlated with tumor burden. The utility of these markers in HCC risk assessment and in HCC prevention should be further evaluated.
While this study is the first report on the composition of lipids in both the liver and plasma and in both NASH and HCC, lipidomic studies in these diseases have been reported.
Overall, there is a good agreement between our study and the two studies of Puri et al. (18, 19) reporting NASH-associated increases in MUFAs:SFA ratio, increases of vaccenic acid and oleic acid and decreases of behenic, lignoceric, linoleic, α-linolenic and DHA acids. In contrast, there was only partial agreement with a recent lipidomic study in HCC (20) . While in both studies, a decrease in lignoceric acid in HCC plasma was observed, our study didn't detect any increase in palmitic acid. Overall, our study demonstrated for the first time that circulating lipid metabolome provides direct information about changes in the liver. We have identified selected fatty acids and fatty acid modifying enzymes that may have protumorigenic functions. Blocking of elovl6, scd1 and fads2 in particular, might provide significant therapeutic benefit to patients predisposed to NASH and HCC. From the viewpoint of cancer prevention, it would also be important to take 
